Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386346 · ClinicalTrials.gov registry record · Phase 1
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
A Phase 1 study of Esophageal Cancer and Malignant Neoplasm of Cardio-esophageal Junction of Stomach, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01386346: Completed Phase 1 study of Esophageal Cancer and Malignant Neoplasm of Cardio-esophageal Junction of Stomach, sponsored by Weill Medical College of Cornell University.
NCT01386346 is a Phase 1 study of Esophageal Cancer and Malignant Neoplasm of Cardio-esophageal Junction of Stomach that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 12 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01386346, a Phase 1 study of Esophageal Cancer and Malignant Neoplasm of Cardio-esophageal Junction of Stomach, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Azacitidine
- DRUG Epirubicin
Study Locations (1)
New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-06 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
What the finished NCT01386346 record still lists
NCT01386346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Capecitabine is the first listed.
NCT01386346 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01386346 about?
NCT01386346 is a clinical study titled "Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer". The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.
What is the current status of trial NCT01386346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-06. Estimated completion is 2018-09.
What conditions does trial NCT01386346 study?
This clinical trial studies the following conditions: Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach.
What interventions are being tested in trial NCT01386346?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Azacitidine (DRUG), Epirubicin (DRUG).
Who is sponsoring clinical trial NCT01386346?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01386346 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01386346's enrollment target sits among peer trials
12 118th of 123 higher than 5 of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia